AstraZeneca Pharma India has announced key changes in its senior management team, effective from 1 April 2026. Dr. Shashank Srinivasan has been appointed as the Medical Director for the Oncology Business Unit, while Mr. Venkat Natarajan has been promoted to Director of the Market Access Business Unit.
Dr. Shashank Srinivasan is a distinguished clinical oncologist and alumnus of Tata Memorial Hospital, Mumbai. He has previously served as a consultant in the GI Cancers Disease Management Group within the Division of Radiation Oncology at Tata Memorial Hospital. Dr. Srinivasan holds a DNB in Radiation Oncology from Max Super Speciality Hospital, Vaishali, and has contributed significantly to oncology research. His career includes a notable tenure at Pfizer, where he led initiatives in the ALK+ NSCLC therapy area. At AstraZeneca, he has served as the Therapy Area Lead for GI and Lung Cancers, driving transformative projects that enhance patient outcomes.
Mr. Venkat Natarajan, a seasoned Market Access professional, has been with AstraZeneca since January 2024. He has played a pivotal role in strengthening the Market Access function, driving strategic access initiatives, expanding patient support programs, and advancing state-level access models. Mr. Natarajan has held Market Access roles at Pfizer, Novartis, and MSD, contributing to access models across government, insurance, and self-pay segments. He holds a Master’s degree in Biochemistry and advanced management qualifications from the Indian School of Business and Symbiosis Institute of Management Studies.
These appointments reflect AstraZeneca Pharma India‘s commitment to strengthening its leadership in the oncology and market access domains, aiming to improve patient care and access to medicines.
Disclaimer: This article is based on a regulatory filing submitted to the National Stock Exchange of India (NSE).